Nexstim and its systems covered in media

Nexstim in Media

The links below provide you with access to news about Nexstim and its nTMS systems in different media channels.

Please note that the list may not be complete and Nexstim does not provide any assurance of the accuracy of the information in these news and may not agree with the opinions presented in them.

YLE Tiedeykkönen: Kivusta ja masennuksesta eroon magneettistimulaatiolla (August 29, 2019)

Finnish Public Broadcasting Company Yle  published  Podcast (in Finnish) about TMS therapy in Helsinki University Hospital where Nexstim SmartFocus® nTMS technology is used. The podcast includes interviews with Nexstim's founder, Professor Risto Ilmoniemi and Clinical Neurophysiologist Selja Vaalto, MD, who has used our TMS system for a long time.

Tiedeykkönen: Kivusta ja masennuksesta eroon magneettistimulaatiolla

Viisas Raha: Terapiahoidoista uutta vauhtia (April 11, 2019)

Finnish Investor Magazine Viisas raha published an article about Nexstim. You can read it on the magazine's online version on p.18 (in Finnish).

Viisas Raha: Terapiahoidoista uutta vauhtia

Investerarbrev: Nexstims system kan vara lösningen för depression – expanderar i USA (April 2, 2019)

Swedish Investor Magazine published a news story based on an interview with our CEO Martin Jamieson (The article is in Swedish).

Investerarbrev: Nexstims system kan vara lösningen för depression – expanderar i USA

YLE: Tinnitus kan vara ett rent helvete – men färsk forskning vid ÅUCS ökar hoppet om ett bättre liv för många patienter (April 6, 2019)

Finnish Broadcasting Company YLE published a tv news and website news article (in Swedish) about Finnish research that looks to magnetic stimulation tech in fight against tinnitus.

Yle: Tinnitus kan vara ett rent helvete – men färsk forskning vid ÅUCS ökar hoppet om ett bättre liv för många patienter

YLE: Elossa 24 Reality TV-series (January 9, 2019)

Finnish reality tv-series Elossa 24h (in Finnish) showed how Nexstim SmartFocus technology has been successfully used in a treatment of a difficult phantom pain. The scenes about the pain treatment are at the following time slots: 11.05-12.30 & at 17.52-19.52.

Elossa 24 Reality TV-series: Season 3, episode 4

HS: Sähköinen ärsytys herättelee halvaantuneita liikkumaan – aivojen ja lihasten yhtä­aikainen stimulaatio on suomalainen oivallus (November 26, 2018)

The biggest newspaper in Finland, Helsingin Sanomat, published a news article about an on-going research in the Helsinki University Hospital where Nexstim's nTMS system is succesfully used in the treatment of incomplete spinal cord injury.

HS: Sähköinen ärsytys herättelee halvaantuneita liikkumaan – aivojen ja lihasten yhtä­aikainen stimulaatio on suomalainen oivallus

Indications for Use in Major Depressive Disorder

FDA:

Nexstim Navigated Brain Therapy (NBT) System 2 is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Nexstim NBT System 2 is intended to be used by trained clinical professionals.

CE Mark :

Nexstim Navigated Brain Therapy System for depression is intended to be used for treatment of major depressive disorder (MDD) by targeting and delivering noninvasive repetitive TMS stimulation to the patient's dorsolateral prefrontal cortex.

Nexstim MRI-Guided and E-Field Navigated Brain Therapy System (Nexstim NBT® System) is indicated for noninvasive mapping of the primary motor cortex of the brain to its cortical gyrus. Nexstim NBT System is indicated for MRI-guided and electric field (or E-field) navigated, noninvasive, repetitive TMS stimulation (rTMS) of the motor cortex as therapy to alleviate chronic unilateral neuropathic pain in adult patients.mNexstim NBT® System is intended to be used by trained clinical professionals.

Indications for Use in Chronic Neuropathic Pain

CE Mark:

In the EU, Nexstim MRI-Guided and E-Field Navigated Brain Therapy System (Nexstim NBT® System) is indicated for noninvasive mapping of the primary motor cortex of the brain to its cortical gyrus. Nexstim NBT System is indicated for MRI-guided and electric field (or E-field) navigated, noninvasive, repetitive TMS stimulation (rTMS) of the motor cortex as therapy to alleviate chronic unilateral neuropathic pain in adult patients.

Nexstim NBT® System is intended to be used by trained clinical professionals.

Indications for Use in Localization of Motor Cortex

FDA and CE-mark:

The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The Nexstim NBS System 5 provides information that may be used in the assessment of the primary motor cortex for pre-procedural planning.

The Nexstim NBS System 5 is not intended to be used during a surgical procedure. The Nexstim NBS System 5 is not intended to be used by trained clinical professionals.

Indications for Use in Localization of Speech Function

FDA and CE-mark:

Nexstim NexSpeech®, when used together with the NBS System 5, is indicated for non-invasive localization of cortical areas that do not contain essential speech function. NexSpeech® provides information that may be used in pre-surgical planning in patients undergoing brain surgery. Intra-operatively, the localization information provided by NexSpeech® is intended to be verified by direct cortical stimulation.

The Nexstim NBS System 5 with NexSpeech® is not intended to be used during a surgical procedure.

The Nexstim NBS System 5 with NexSpeech® is intended to be used by trained clinical professionals.